Bristol-Myers Squibb (BMY) beat expectations in FY2026 on revenue of $98.4B versus the $96.4B estimate (-1.7% YoY) and EPS of $0.63. Below is the full Bristol-Myers Squibb earnings breakdown — the risk-adjusted verdict, price forecast, technicals, options and hedge-fund 13F holdings, decoded in plain English.
$98.4B (vs $96.4B est · +2.1% surprise · -1.7% YoY)
EPS
$0.63 (vs $0.61 est · +3.3% surprise · -5.3% YoY)
Share price
$88.52 (+0.5%)
Market cap
$950.0B
What you'll find
Next Bristol-Myers Squibb (BMY) earnings date, the expected move and the estimates priced in
A clear Beat / Miss / In-line / Mixed verdict the moment Bristol-Myers Squibb reports
Revenue & EPS versus estimates, guidance and segment trends
Multi-lens price forecast — analyst, quant, technical and options views
Deep research: red flags, risk decoder and earnings-call sentiment
Technicals, options / implied volatility and unusual-activity signals
Hedge-fund and legendary-investor 13F holdings in Bristol-Myers Squibb (BMY)
Side-by-side peer and historical earnings comparison
Frequently asked questions
When is Bristol-Myers Squibb's next earnings date?
Bristol-Myers Squibb's (BMY) next scheduled earnings date is Feb 6, 2025. Magnisto shows the confirmed date, the options-implied expected move and the revenue and EPS estimates Wall Street is modeling into the report.
Did Bristol-Myers Squibb (BMY) beat or miss earnings?
In FY2026, Bristol-Myers Squibb (BMY) posted beat results — revenue of $98.4B versus the $96.4B estimate (+2.1% surprise) and EPS of $0.63 versus $0.61 expected (+3.3% surprise). Magnisto decodes every Bristol-Myers Squibb (BMY) report into a clear Beat, Miss, In-line or Mixed verdict and checks whether guidance was raised, held or cut.
What is the forecast for Bristol-Myers Squibb (BMY) stock?
Magnisto blends analyst price targets, quantitative research, technical trend and options-implied moves into a scenario range for Bristol-Myers Squibb (BMY), anchored to the current $88.52 share price, so you can weigh the bull, base and bear cases for Bristol-Myers Squibb side by side.
Is Bristol-Myers Squibb (BMY) a buy right now?
Magnisto does not give buy or sell tips. It gives you the institutional-grade evidence — the verdict, valuation, risks, technicals and hedge-fund 13F flows — so you can decide whether Bristol-Myers Squibb fits your own thesis and risk profile. This is research, not investment advice.